Overview
Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion
Status:
Recruiting
Recruiting
Trial end date:
2022-08-01
2022-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Comparing time to recurrence of macular edema after an initial loading dose of at least three monthly anti VEGF injections (aflibercept or ranibizumab) for macular edema in BRVO.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
St. Erik Eye HospitalTreatments:
Aflibercept
Ranibizumab
Criteria
Inclusion Criteria:- BRVO naïve patients, disease duration 1-6 months, BCVA 23-73 ETDRS letters
(20/40-20/320), macula edema with intraretinal cysts and CRT > 300 micrometers
(Cirrus)
Exclusion Criteria:
- BRVO with neovascular component, intraocular surgery during the previous 3 months,
earlier vitreoretinal surgery, vascular retinopathy of other cause, intraocular
infection/inflammation, myocardial infarction och cerebrovascular stroke during the
last 3 months.